IL17A and type 1 diabetes mellitus: The potential of targeting the IL-17A/RORγt axis is further underscored by the novel RORγt inverse agonist, panaxadiol, demonstrated to suppress IL-17A production and alleviate inflammation, offering a promising therapeutic approach for T1D (Tian et al., 2023).